文献速递前列腺癌

ZRSR2过表达是去势抵抗性前列腺癌发生中的频发早期事件

ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-02-10

本研究利用去势后发展为去势抵抗性前列腺癌(CRPC)的激素初治前列腺癌(HNPC)患者来源异种移植(PDX)模型,通过转录组分析寻找去势后早期表达变化的基因。发现ZRSR2在CRPC早期即显著上调并持续高表达,临床CRPC样本中亦高表达,且与患者治疗结局差相关;敲低ZRSR2可抑制增殖并延缓细胞周期,部分通过抑制Cyclin D1(CCND1)通路。

要点

  • ZRSR2在去势后CRPC早期即显著上调,并在完全发展的CRPC中持续高表达。
  • 临床CRPC样本中ZRSR2高表达,且与前列腺癌患者治疗结局差相关。
  • 敲低ZRSR2可抑制前列腺癌细胞增殖并延缓细胞周期,部分通过抑制CCND1通路。

核心结论

  • 利用HNPC PDX模型鉴定ZRSR2为CRPC发生的潜在早期驱动基因。

研究设计与样本

  • 在Living Tumor Laboratory建立HNPC PDX模型,去势后不同时间点行转录组分析差异表达基因。
  • 聚焦去势后短期、CRPC完全发展前表达变化的基因,并用前列腺癌患者数据库验证临床相关性。

主要发现

  • ZRSR2在PDX模型CRPC早期显著上调,完全发展的CRPC PDX中持续高表达。
  • 临床CRPC样本中亦观察到ZRSR2高表达。
  • 前列腺癌样本中ZRSR2升高与患者治疗结局差相关。
  • 敲低ZRSR2降低前列腺癌细胞增殖并延缓细胞周期,至少部分通过抑制CCND1通路。

临床怎么用

  • ZRSR2高表达可能作为CRPC早期预警与预后不良的候选标志物。
  • 靶向ZRSR2或其下游CCND1通路或为CRPC防治提供潜在方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen deprivation therapy (ADT) remains the leading systemic therapy for locally advanced and metastatic prostate cancers (PCa). While a majority of PCa patients initially respond to ADT, the durability of response is variable and most patients will eventually develop incurable castration-resistant prostate cancer (CRPC). Our research objective is to identify potential early driver genes responsible for CRPC development. METHODS: We have developed a unique panel of hormone-naïve PCa (HNPC) patient-derived xenograft (PDX) models at the Living Tumor Laboratory. The PDXs provide a unique platform for driver gene discovery as they allow for the analysis of differentially expressed genes via transcriptomic profiling at various time points after mouse host castration. In the present study, we focused on genes with expression changes shortly after castration but before CRPC has fully developed. These are likely to be potential early drivers of CRPC development. Such genes were further validated for their clinical relevance using data from PCa patient databases. ZRSR2 was identified as a top gene candidate and selected for further functional studies. RESULTS: ZRSR2 is significantly upregulated in our PDX models during the early phases of CRPC development after mouse host castration and remains consistently high in fully developed CRPC PDX models. Moreover, high ZRSR2 expression is also observed in clinical CRPC samples. Importantly, elevated ZRSR2 in PCa samples is correlated with poor patient treatment outcomes. ZRSR2 knockdown reduced PCa cell proliferation and delayed cell cycle progression at least partially through inhibition of the Cyclin D1 (CCND1) pathway. CONCLUSION: Using our unique HNPC PDX models that develop into CRPC after host castration, we identified ZRSR2 as a potential early driver of CRPC development.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. He H, Hao J, Dong X, et al. ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development. Prostate Cancer Prostatic Dis. 2021. PMID: 33568749. doi:10.1038/s41391-021-00322-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。